[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621060":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":31,"responsibleParty":33,"collaborators":31,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":31,"enrollmentInfo":46,"targetDuration":31,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":31,"overallStatus":56,"whyStopped":31,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":31},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cirrhosis","EXPERIMENTAL","Adult participants (≥18 years old) with clinically confirmed liver cirrhosis, classified as Child-Pugh class A-C, with clinical and morphological signs of portal hypertension",[13],"Drug: SonoVue",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","SonoVue","microbubbles infusion and ultrasound",[9],[21],"INN-sulphur hexafluoride",[23],{"name":24,"affiliation":5,"role":25},"Fabrizio Pizzolante","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Fabrizio Pizzolante, MD Phd","CONTACT","+390630159650",null,"fabrizio.pizzolante@policlinicogemelli.it",{"type":25,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Pizzolante Fabrizio","MD, PhD","100621060","liver-cirrhosis-complicated-by-clinically-significant-portal-hypertension-100621060",false,"NCT07365709","Liver Cirrhosis Complicated by Clinically Significant Portal Hypertension","Liver Cirrhosis Complicated by Clinically Significant Portal Hypertension: the Role of Contrast-enhanced Ultrasound and Splenic Elastography for Non-invasive Assessment","CIRCE","Inclusion Criteria:\n\nIndividuals of both sexes aged 18 years or over; Subjects diagnosed with liver cirrhosis. Subjects who have undergone hepatic venous pressure gradient (HVPG) measurement to assess portal hypertension, and\u002For show indirect clinical signs of significant portal hypertension, such as oesophageal varices or porto-systemic collateral circulation.\n\nCirrhotic subjects who must undergo contrast-enhanced ultrasound as part of regular hepatological follow-up.\n\nSubjects who have given their informed consent.\n\nExclusion Criteria:\n\nSubjects aged under 18 years; Subjects with cholestatic disease Subjects diagnosed with clinically significant portal hypertension of non-cirrhotic aetiology.\n\nSubjects diagnosed with ascites Subjects diagnosed with splanchnic thrombosis Subjects presenting with spleno-portal flow reversal Subjects who are allergic to ultrasound contrast media Subjects who have not given their informed consent.","ALL","18 Years",{"count":47,"type":48},107,"ESTIMATED","INTERVENTIONAL",[51],"NA","Portal hypertension is a major complication of cirrhosis. HVPG is the diagnostic gold standard but is invasive. Non-invasive tools such as spleen stiffness measurement (SSM) and CEUS show promise for assessing CSPH, though they have not yet been compared directly. A multimodal ultrasound approach may provide a reliable alternative to HVPG.",[54,55,9],"Portal Hypertension","Spleen Disease","NOT_YET_RECRUITING","2026-01-16",{"date":59,"type":60},"2026-01-26","ACTUAL",{"date":62,"type":48},"2026-02-01",{"date":64,"type":48},"2026-12-31",{"name":5,"class":6}]